Longboard Pharmaceuticals clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   LP352 in Children and · Dravet Syndrome (DS)

   Enrollment closed, study ongoing

   Also in this update: Primary completion pushed from Aug 21, 2026 to Dec 31, 2026; Study completion pushed from Oct 2, 2026 to Dec 31, 2026

   Longboard Pharmaceuticals·Phase 3· NCT06660394· Registry history of NCT06660394 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

2. Minor

   LP352 in Children and · Developmental and Epileptic Encephalopathy…LP352 in Children and · Developmental and Epileptic Encephalopathy (DEE)

   Trial sites expanded: 83 → 88 locations

   Longboard Pharmaceuticals·Phase 3· NCT06908226· Registry history of NCT06908226 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.